Mr. Shane Madden reports

HYDREIGHT TECHNOLOGIES CLOSES STRATEGIC INVESTMENT IN INSU THERAPEUTICS

Hydreight Technologies Inc. has closed a $300,000 strategic investment in Insu Therapeutics Inc. through the acquisition of 800,000 units at a price of 37.5 cents per unit, pursuant to a subscription agreement dated March 4, 2026, between the company and Insu. The investment represents a measured allocation of capital aligned with Hydreight's broader platform and ecosystem strategy.

Hydreight's investment reflects the company's strategy of exploring innovations that may enhance the capabilities of its national pharmacy and telehealth infrastructure. Hydreight continues to expand its national pharmacy network and platform licensee ecosystem, and the company believes innovations in therapeutic delivery could further support the growing range of treatments being offered through its infrastructure.

Hydreight operates a national health care infrastructure platform that connects physicians, pharmacies and patients through its compliant telehealth network operating across all 50 U.S. states. As new therapies emerge -- including peptide-based treatments such as insulin, GLP-1 agonists like Ozempic, metabolic therapies and hormone treatments such as testosterone -- the company believes innovations in delivery technologies, including Insu's novel buccal delivery platform, may improve patient convenience and adherence, and could support the range of services offered through Hydreight's network.

Hydreight's national infrastructure -- including its physician network, pharmacy partnerships and compliant telehealth platform operating across all 50 states -- positions the company to support a growing range of health care services as new therapies emerge. As peptide-based medicines expand across multiple therapeutic areas, Hydreight believes its role as an enabling health care infrastructure provider allows the company to remain close to innovations in the category while continuing to scale its core digital health platform.

Each unit comprises one common share of Insu and one common share purchase warrant of Insu, with each warrant exercisable to acquire one Insu share at a price of $1 for a period of two years from the date of issuance. The aggregate consideration for the units was $300,000, which was paid by the company in cash (50 per cent, being $150,000) and in common shares of the company (50 per cent, being 37,037 common shares of the company at a deemed price of $4.05).

Strategic rationale for investment

Hydreight's investment in Insu reflects the company's strategy of selectively partnering with emerging health care technologies that may enhance the capabilities of its national digital health and pharmacy network.

Unlike traditional biotechnology companies focused on discovering new drug molecules, Insu Therapeutics is developing a proprietary buccal delivery platform designed to enable certain, FDA-approved (U.S. Food and Drug Administration) peptide therapeutics to be absorbed through the oral mucosa rather than through injection or gastrointestinal oral delivery. Insu's development strategy focuses on reformulating already-approved peptide therapeutics and advancing them through the FDA's 505(b)(2) regulatory pathway, which allows companies to leverage existing safety and efficacy data for approved drugs rather than undertaking the traditional full phase 1 to 3 drug discovery and development programs. Hydreight believes this approach may offer a more efficient development pathway compared with traditional drug discovery programs.

Insu Therapeutics has completed its animal study program for insulin and is now advancing a similar program for semaglutide (Ozempic) -- two milestones that set the stage for a scalable manufacturing partnership with a world-class CDMO. This collaboration will cover the full development spectrum, from early formulation through clinical trial supply to large-scale commercial manufacturing, all within a GMP-certified (good manufacturing practice) facility. The partnership is designed to compress timelines and control costs by leveraging deep regulatory expertise and specialized infrastructure. Insu is targeting completion of the manufacturing program within 12 months, with an FDA submission for clinical study approval planned for early 2027.

Hydreight believes Insu's platform unlocks a smarter path to peptide therapeutics -- one that prioritizes patient-friendly delivery and positions the company ahead of a growing shift away from injectable treatments.

The company's investment of $300,000, consisting of $150,000 in cash and $150,000 in Hydreight common shares, represents a disciplined and limited capital allocation intended to provide Hydreight with early exposure to a potential next-generation peptide delivery platform while maintaining focus on its core digital health care infrastructure business.

Hydreight's pharmacy network and several of the company's platform licensees have expressed growing interest in peptide delivery options beyond injections and traditional oral formulations as demand for peptide-based therapies continues to expand. If successful, Insu's technology could allow Hydreight to leverage its national pharmacy and telehealth infrastructure to support distribution of peptide therapeutics in the United States. Under the terms of its relationship with Insu, Hydreight has secured exclusive U.S. rights to distribute peptide therapeutics utilizing Insu's buccal delivery technology, subject to successful development and regulatory approvals.

Hydreight believes its integrated telehealth platform, physician network and national pharmacy infrastructure position the company to support the growing adoption of peptide-based therapies while continuing to expand the services delivered through its national health care network.

Recent rapid growth in peptide-based therapeutics -- including GLP-1 medications used for diabetes and weight management -- has highlighted the importance of delivery innovation in this rapidly expanding category. Industry analysts estimate the global GLP-1 market could exceed $40-billion (U.S.) annually by the early 2030s (Morgan Stanley Research, 2023; Goldman Sachs Global Investment Research, 2024). While GLP-1 therapies have received significant attention, peptide medicines represent a much broader and growing class of therapeutics across multiple indications, and researchers continue exploring new delivery mechanisms that may improve patient convenience and adherence.

Management commentary

Shane Madden, chief executive officer of Hydreight, commented:

"Hydreight's focus remains on building one of the largest compliant digital health care infrastructure platforms in the United States, connecting providers, pharmacies and patients through our national network. This investment allows us to explore a potentially important innovation in peptide delivery while maintaining disciplined capital allocation and focus on scaling our core platform. As peptide-based therapies continue to expand across health care, we believe Hydreight's national pharmacy and telehealth infrastructure positions the company well as an infrastructure layer supporting peptide-based therapies across a rapidly expanding category within the broader peptide therapeutics ecosystem."

Dr. Anubhav Pratap-Singh, co-founder of Insu Therapeutics, added:

"Our buccal delivery platform is designed to enable peptide medicines to be absorbed through the oral mucosa, bypassing the gastrointestinal tract. By leveraging the FDA's 505(b)(2) pathway and focusing on already-approved peptide therapeutics, we aim to accelerate development timelines while exploring more convenient delivery options for patients."

Regulatory disclosure (Multilateral Instrument 61-101)

The company relied on Section 5.5(b) of MI 61-101 as the exemption from the formal valuation requirements of MI 61-101 in respect of the subscription of the units of Insu, being a related party (as such term is defined under MI 61-101) of the company, as the common shares of the company are not listed on a specified market under MI 61-101.

The company relied on Section 5.7(a) of MI 61-101 as the exemption from the minority approval requirements of MI 61-101 in respect of the subscription of the units as neither the fair market value of the subject matter of, nor the fair market value of the consideration for, such issuances exceeded 25 per cent of the company's market capitalization.

About Hydreight Technologies Inc.

Hydreight Technologies operates a national digital health care platform that connects health care providers, pharmacies and patients through a fully integrated telehealth and compliance infrastructure. The company's platform supports a growing network of licensed health care professionals and pharmacy partners delivering services and therapies across all 50 U.S. states.

Hydreight is building one of the largest mobile clinic networks in the United States. Its proprietary platform hosts a network of over 3,000 nurses, 300-plus physicians and a pharmacy network serving all 50 states.

The platform includes a built-in suite of tools for accounting, documentation, sales, inventory, booking and patient management, enabling licensed health care professionals to provide services directly to patients at home, office or hotel.

Hydreight maintains a national 503B pharmacy network and works closely with a U.S. certified e-script and telemedicine provider network to deliver compliant health care solutions across the United States. Through its national network of providers and pharmacy partners, Hydreight's platform supports a growing range of health care services and therapies as new treatment innovations emerge across the health care ecosystem, including peptide-based medicines.

We seek Safe Harbor.